Search

BI Cares: Supporting Ukraine

Our family-owned company condemns the ongoing military aggression against Ukraine, and have maintained our support for those in need by providing financial and in-kind donations through our Boehringer Ingelheim Cares Foundation.

Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program

How Boehringer Ingelheim US Helps Injured Veterans | Boehringer Ingelheim US

Read more on how Boehringer Ingelheim supports injured veterans in making a fresh start through the use of service dogs, with the Warrior Canine Connection.

BI initiates Study of Sequencing in EGFR Lung Cancer | BI US

Boehringer Ingelheim has initiated a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced NSCLC.

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

Topline results from Boehringer's Phase III IPF Study

Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis

Bigger Role in Ensuring Food Security | Boehringer Ingelheim US

As the population of the earth grows, animal health becomes fundamental in ensuring well-being and the global protein supply. Click here to find out more.

Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment

Cafeteria Crews Cook for Community | Boehringer Ingelheim US

Read more on how BI cafeteria crews are supporting their communities by cooking over 500 meals a day for first responders & others during the pandemic.

Yankees Baseball Legend Bernie Williams Raises Awareness of Devastating Lung Disease – IPF – in Honor of his Dad

Yankees Baseball Legend Bernie Williams Raises Awareness Of Devastating Lung Disease – Ipf – In Honor Of His Dad

Embracing Differences: Our journey to diversity, equity, and inclusion

New Documentary Highlights Ranch’s Commitment to Cattle Health

Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation

Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US

Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.

FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US

FDA approves PRADAXA for the prophylaxis of DVT & PE in patients who have undergone a hip replacement. View ISI, PI and Med Guide.

FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US

FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

Ways we’re protecting the planet

Click here to read a few examples of the sustainability practices we’ve put in place at our U.S. HQ, to protect the planet for a more sustainable tomorrow.

Adopting shelter pets: Employees make a difference at work and home

From Finance to Pharma

Celebrating the power of people and their experiences: Observations for Hispanic/ Latinx Heritage Month

Our Boehringer colleagues share how their experiences with their culture have influenced their approach to life and work.

The liver and its vital connection to our overall health

How the liver is part of our interconnected cardiovascular, renal and metabolic system and why we need to look after it

Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

Medicines reach record number of people, net sales rise

Novel antibody shows potential to transform treatment of rare form of psoriasis

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers